Table of Contents
International Journal of Proteomics
Volume 2012, Article ID 921901, 10 pages
Review Article

Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care

1Department of Surgery, Tokyo Medical University, 6-7-1 Nishi Shinjuku Shinjuku-ku, Tokyo 160-0023, Japan
2Graduate School of Medical Science, Yokohama City University, 3-9 Fukuura Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
3Medical ProteoScope, 1-6 Suehiro-cho, Tsurumi-ku, Yokohamashi, Kanagaewa, 230-0045, Japan
4Thoracic Surgery, Niizashiki Chuo General Hospital, 7-2 1-chome, Tohoku, Niiza, Saitama 352-0001, Japan

Received 9 December 2011; Accepted 28 February 2012

Academic Editor: Tadashi Kondo

Copyright © 2012 Toshihide Nishimura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


An overview on targeted personalized medicine is given describing the developments in Japan of lung cancer patients. These new targeted therapies with novel personalized medicine drugs require new implementations, in order to follow and monitor drug efficacy and outcome. Examples from IRESSA (Gefitinib) and TARCEVA (Erlotinib) treatments used in medication of lung cancer patients are presented. Lung cancer is one of the most common causes of cancer mortality in the world. The importance of both the quantification of disease progression, where diagnostic-related biomarkers are being implemented, in addition to the actual measurement of disease-specific mechanisms relating to pathway signalling activation of disease-progressive protein targets is summarised. An outline is also presented, describing changes and adaptations in Japan, meeting the rising costs and challenges. Today, urgent implementation of programs to address these needs has led to a rebuilding of the entire approach of medical evaluation and clinical care.